Nervgen Pharma Corp Stock Performance
| NGENF Stock | USD 1.55 0.05 3.33% |
NervGen Pharma has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.61, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NervGen Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding NervGen Pharma is expected to be smaller as well. NervGen Pharma Corp right now secures a risk of 3.94%. Please verify NervGen Pharma Corp expected short fall, and the relationship between the value at risk and daily balance of power , to decide if NervGen Pharma Corp will be following its current price movements.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in NervGen Pharma Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating basic indicators, NervGen Pharma may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
| Begin Period Cash Flow | 5.6 M | |
| Total Cashflows From Investing Activities | -45.1 K |
NervGen |
NervGen Pharma Relative Risk vs. Return Landscape
If you would invest 133.00 in NervGen Pharma Corp on January 30, 2024 and sell it today you would earn a total of 22.00 from holding NervGen Pharma Corp or generate 16.54% return on investment over 90 days. NervGen Pharma Corp is currently producing 0.1191% returns and takes up 3.944% volatility of returns over 90 trading days. Put another way, 34% of traded otc stocks are less volatile than NervGen, and 98% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NervGen Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NervGen Pharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as NervGen Pharma Corp, and traders can use it to determine the average amount a NervGen Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0302
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | NGENF | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.94 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average NervGen Pharma is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NervGen Pharma by adding it to a well-diversified portfolio.
NervGen Pharma Fundamentals Growth
NervGen OTC Stock prices reflect investors' perceptions of the future prospects and financial health of NervGen Pharma, and NervGen Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NervGen OTC Stock performance.
| Return On Equity | -1.42 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 48.78 M | |||
| Shares Outstanding | 58.68 M | |||
| Price To Book | 5.13 X | |||
| EBITDA | (11.33 M) | |||
| Cash And Equivalents | 11.65 M | |||
| Cash Per Share | 0.20 X | |||
| Total Debt | 324.69 K | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (8.27 M) | |||
| Earnings Per Share | (0.28) X | |||
| Total Asset | 17.9 M | |||
About NervGen Pharma Performance
To evaluate NervGen Pharma Corp OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when NervGen Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare NervGen OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand NervGen Pharma Corp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents NervGen's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about NervGen Pharma Corp performance evaluation
Checking the ongoing alerts about NervGen Pharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for NervGen Pharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NervGen Pharma Corp may become a speculative penny stock | |
| NervGen Pharma Corp had very high historical volatility over the last 90 days | |
| NervGen Pharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (12.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NervGen Pharma Corp has accumulated about 11.65 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2. | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing NervGen Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NervGen Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NervGen Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NervGen Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NervGen Pharma's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of NervGen Pharma's otc stock. These opinions can provide insight into NervGen Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for NervGen OTC Stock analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stocks Directory Find actively traded stocks across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |